Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s Gardasil Records $70 Mil. In Sales In Q3

This article was originally published in The Pink Sheet Daily

Executive Summary

Managed care plans representing over 90% of covered lives of girls and women nine to 26 have added HPV vaccine to their respective formularies, Merck reports.

You may also be interested in...



FDA Denies Priority Review For GlaxoSmithKline’s HPV Vaccine Cervarix

Decision could give Merck’s Gardasil an extra four months without HPV vaccine competition.

FDA Denies Priority Review For GlaxoSmithKline’s HPV Vaccine Cervarix

Decision could give Merck’s Gardasil an extra four months without HPV vaccine competition.

GSK Wagers On Cervarix In Head-To-Head Trial Against Gardasil

Trial will be the first to directly compare sustained immune response in women treated with the two cervical cancer vaccines.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel